Sanofi India Ltd
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
- Market Cap ₹ 13,953 Cr.
- Current Price ₹ 6,064
- High / Low ₹ 7,600 / 4,146
- Stock P/E 31.6
- Book Value ₹ 374
- Dividend Yield 1.93 %
- ROCE 49.2 %
- ROE 47.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 28.6 days to 21.4 days
Cons
- Stock is trading at 16.2 times its book value
- Debtor days have increased from 32.9 to 41.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250 BSE SmallCap BSE 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
1,996 | 2,013 | |
1,508 | 1,522 | |
Operating Profit | 488 | 491 |
OPM % | 24% | 24% |
317 | 78 | |
Interest | 2 | 2 |
Depreciation | 36 | 37 |
Profit before tax | 767 | 531 |
Tax % | 21% | 22% |
603 | 413 | |
EPS in Rs | 262.13 | 179.70 |
Dividend Payout % | 64% | 65% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -25% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 5% |
3 Years: | 12% |
1 Year: | 19% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 47% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
Equity Capital | 23 | 23 |
Reserves | 992 | 838 |
19 | 19 | |
681 | 732 | |
Total Liabilities | 1,715 | 1,612 |
315 | 312 | |
CWIP | 16 | 18 |
Investments | 0 | 0 |
1,384 | 1,281 | |
Total Assets | 1,715 | 1,612 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
230 | 462 | |
38 | -180 | |
-878 | -392 | |
Net Cash Flow | -610 | -111 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
Debtor Days | 24 | 42 |
Inventory Days | 254 | 186 |
Days Payable | 112 | 151 |
Cash Conversion Cycle | 167 | 77 |
Working Capital Days | 36 | 21 |
ROCE % | 49% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
25 Apr - INR 39.02 Cr tax demand for AY 2022-23; company to appeal; amnesty reliefs for 2018-19 and 2019-20.
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
24 Apr - Tax demand and penalty of Rs.5.25 crore by GST authority; company to appeal order.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Apr
-
Business Responsibility and Sustainability Reporting (BRSR)
22 Apr - Sanofi India publishes detailed 2024 Business Responsibility and Sustainability Report covering ESG and employee welfare.
-
Notice Of The Sixty Ninth Annual General Meeting
22 Apr - Sanofi India AGM on May 15, 2025; final dividend Rs.117/share; director re-appointments and auditor appointments.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
May 2023Transcript PPT
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptNotesPPT
Parent Company[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.